Claims

1. A compound of formula (Ib),



(Ib),

or a pharmaceutically acceptable salt thereof; wherein

n is 1 or 2;

R^1, R^2, and R^3 are independently selected from the group consisting of: hydrogen, alkyl, and halogen;

Y is a nitrogen-containing ring or a nitrogen-containing chain;

A is a monocyclic ring, a bicyclic ring, or a tricyclic ring, and A is attached via a sp^3 hybridised carbon to the rest of the compound;

L is a C_{1-6} alkyl linker or L is absent; if L is absent, A is directly attached to the cyclic oxime; and

A and Y are optionally substituted.

2. The compound according to claim 1, wherein A is selected from the group consisting of: a monocyclic ring and a bicyclic ring; and

b) comprises 1, 2 or 3 nitrogen atoms; and/or

c) comprises 0, 1, 2 or 3 oxygen atoms.

3. The compound according to any one of claims 1-2, wherein A is of formula (II):



(II); wherein

z^1 and z^2 are independently selected from the group consisting of: 0, 1, 2, and 3;

Q is selected from the group consisting of:

 (IIa),  (IIb),  (IIc), and  (IId);

R^4 is selected from the group consisting of: hydrogen, alkyl, amino, alkoxy, acyl, amido, aralkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl;

R^5 is selected from the group consisting of: hydrogen, alkyl, aralkyl, hydroxy, alkoxy, and amino;

each R^6 is independently selected from the group consisting of: hydrogen, alkyl, alkoxy, hydroxy, amino, amido, and halogen;

each R^7 is independently selected from the group consisting of: hydrogen, alkyl, alkoxy, hydroxy, amino, amido, and halogen;

each R^8 is independently selected from the group consisting of: hydrogen, alkyl, alkoxy, hydroxy, amino, amido, and halogen; and

each R^9 is independently selected from the group consisting of: hydrogen, alkyl, alkoxy, hydroxy, amino, amido, and halogen.

4. The compound according to any one of claims 1-3, wherein A is of formula (II) and Q is of formula (IIa).

5. The compound according to any one of claims 1-4, wherein L is of formula (III)

 (III); wherein

v is 0 or 1; if v is 0, L is absent;

each R^{10} is independently selected from the group consisting of: hydrogen and alkyl;

each R^{11} is independently selected from the group consisting of: hydrogen and alkyl;

if both R^{10} and R^{11} are alkyl, R^{10} and R^{11} are optionally connected to form a C_{3-6} ring.

6. The compound according to any one of claims 3-5, wherein R^5 is selected from the group consisting of:



(R^5a);



(R^5b); and



(R^5c);

or any tautomer thereof,

wherein a is 0, 1, 2, or 3;

X^1, X^2, X^3, X^4, and X^5 independently are selected from the group consisting of: C, CH, and N; and

each one, two, or three Subst. is independently selected from the group consisting of: hydrogen, alkyl, halogen, hydroxy, alkoxy, amino, amido, acyl, cycloalkyl, and heterocycloalkyl.

7. The compound according to any one of claims 1-6, wherein A is of formula (II) and L is of formula (III), wherein L-A is selected from the group consisting of:









8. The compound according to any one of claims 1-6, wherein A is selected from the group consisting of:





9. The compound according to any one of the preceding claims, wherein Y is a nitrogen-containing ring, wherein the nitrogen-containing ring is monocyclic or bicyclic.

10. The compound according to any one of the preceding claims, wherein Y is selected from the group consisting of:



11. The compound according to any one of the preceding claims, wherein the compound is selected from the group consisting of:






,

,

,


























,

,

,












,

,

,

,

,

,

,

,

,

,
and 
.

12. The compound according to any one of the preceding claims, wherein the compound is a GBA inducer and increases glucocerebrosidase (GBA) enzyme levels and/or GBA enzyme activity.

13. Use of the compound as defined in any one of the preceding claims in the manufacture of a medicament for treating Parkinson's disease (PD) in a subject.